Update on the Pharmacogenomics of Proton Pump Inhibitors
A large segment of the CYP2C19 rapid metabolizer subgroup is nonresponder to the PPI treatment, only partial symptom relief in GERD, more frequent unsuccessful eradication therapy and lower ...
read more